Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;60(4):357-66.
doi: 10.1007/s00011-010-0278-1. Epub 2010 Nov 10.

Protective effect of Gö6976, a PKD inhibitor, on LPS/D: -GalN-induced acute liver injury in mice

G J Duan  1 , J Zhu, C Y Xu, J Y Wan, L Zhang, X D Ge, L M Liu, Y S Liu
Affiliations

Protective effect of Gö6976, a PKD inhibitor, on LPS/D: -GalN-induced acute liver injury in mice

G J Duan et al. Inflamm Res. 2011 Apr.

Abstract

Objective: Protein kinase D (PKD) is a newly described serine/threonine protein kinase that plays a pivotal role in inflammatory response. In the present study, we examined the protective effect of Gö6976, a PKD inhibitor, on lipopolysaccharide (LPS) and D: -galactosamine (D: -GalN)-induced acute liver injury in mice.

Materials and methods: Mice were pretreated intraperitoneally with Gö6976 30 min before LPS/D: -GalN administration . The mortality and degree of hepatic injury was subsequently assessed.

Results: The results indicated that LPS/D: -GalN administration markedly induced hepatic PKD activation, lethality and liver injury, while pretreatment of the PKD inhibitor Gö6976 significantly inhibited LPS-induced PKD activation, improved the survival of LPS/D: -GalN-administered mice and attenuated LPS/D: -GalN-induced liver injury, as evidenced by reduced levels of serum aminotransferases as well as reduced histopathological changes. In addition, the protective effects of Gö6976 were paralleled by suppressed activation of mitogen-activated protein kinases (MAPKs), decreased expression of tumor necrosis factor-α (TNF-α) and adhesion molecules, and reduced apoptosis and myeloperoxidase (MPO) activity in liver.

Conclusions: Our experimental data indicated that Gö6976, a PKD inhibitor, could effectively prevent LPS/D: -GalN-induced acute liver injury by inhibition of MAPKs activation to reduce TNF-α production. This suggests the potential pharmacological value of PKD inhibitors in the intervention of inflammation-based liver diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Gene Med. 2009 Mar;11(3):229-39 - PubMed
    1. Ann N Y Acad Sci. 2008 Nov;1143:1-20 - PubMed
    1. Crit Care Med. 2007 Oct;35(10):2408-16 - PubMed
    1. J Biol Chem. 1994 Feb 25;269(8):6140-8 - PubMed
    1. Exp Mol Pathol. 2009 Aug;87(1):20-6 - PubMed

Publication types

MeSH terms